Rigosertib

Rigosertib is an inhibitor of PLK and AKT used in studies of PI3K-Akt-mTOR Signaling and Cell Cycle Regulation and related signaling programs. In practice, this places the compound in experiments that measure growth-factor signaling, survival control, and nutrient-sensing outputs and checkpoint control, mitotic progression, and proliferation timing in apoptosis, cancer, and cell cycle models.

By inhibiting PLK and AKT, Rigosertib can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and checkpoint control, mitotic progression, and proliferation timing. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and cell cycle models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving PLK and AKT
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and Cell Cycle Regulation and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Rigosertib is appropriate when a defined chemical perturbant is needed to connect PLK and AKT with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and cell cycle models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.